Publication:
Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.

Simple item page
dc.contributor.authorCorma-Gomez, Anaïs
dc.contributor.authorFernandez-Fuertes, Marta
dc.contributor.authorGarcia, Estefania
dc.contributor.authorFuentes-Lopez, Ana
dc.contributor.authorGomez-Ayerbe, Cristina
dc.contributor.authorRivero-Juarez, Antonio
dc.contributor.authorDominguez, Carmen
dc.contributor.authorSantos, Marta
dc.contributor.authorViñuela, Laura
dc.contributor.authorPalacios, Rosario
dc.contributor.authorReal, Luis M
dc.contributor.authorRivero, Antonio
dc.contributor.authorMacias, Juan
dc.contributor.authorPineda, Juan A
dc.contributor.authorGarcia, Federico
dc.contributor.funderSpanish Network for AIDS Investigation
dc.contributor.funderISCIII Subdireccion General de Evaluacion and the European Fund
dc.contributor.funderServicio Andaluz de Salud
dc.contributor.funderMinisterio de Ciencia, Promocion y Universidades of Spain
dc.date.accessioned2023-05-03T14:53:12Z
dc.date.available2023-05-03T14:53:12Z
dc.date.issued2022-05-14
dc.description.abstractThe aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts
dc.description.versionSi
dc.identifier.citationCorma-Gómez A, Fernández-Fuertes M, García E, Fuentes-López A, Gómez-Ayerbe C, Rivero-Juárez A, et al. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clin Microbiol Infect. 2022 Nov;28(11):1492-1498
dc.identifier.doi10.1016/j.cmi.2022.05.018
dc.identifier.essn1469-0691
dc.identifier.pmcPMC9144847
dc.identifier.pmid35640840
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144847/pdf
dc.identifier.unpaywallURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144847
dc.identifier.urihttp://hdl.handle.net/10668/22132
dc.issue.number11
dc.journal.titleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
dc.journal.titleabbreviationClin Microbiol Infect
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationHospital Universitario San Cecilio
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationÁrea de Gestión Sanitaria Sur de Sevilla
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.number1492-1498
dc.provenanceRealizada la curación de contenido 06/09/2024
dc.publisherElsevier
dc.pubmedtypeMulticenter Study
dc.pubmedtypeJournal Article
dc.relation.projectIDRD16/0025/0040
dc.relation.projectIDCM19/00251
dc.relation.projectIDB-0061-2021
dc.relation.projectIDCP18/00111
dc.relation.projectIDINT20-00028
dc.relation.publisherversionhttps://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00276-2/fulltext
dc.rights.accessRightsopen access
dc.subjectCD4 T-cell counts
dc.subjectHumoral response
dc.subjectPeople living with HIV
dc.subjectSARS-CoV-2
dc.subjectVaccine
dc.subjectÁrea de Gestión Sanitaria Sur de Sevilla
dc.subject.decsARN mensajero
dc.subject.decsAnticuerpos antivirales
dc.subject.decsAnticuerpos neutralizantes
dc.subject.decsGlicoproteína de la espiga del coronavirus
dc.subject.decsInfecciones por VIH
dc.subject.decsInmunoglobulina G
dc.subject.decsSíndromes de inmunodeficiencia
dc.subject.meshHumans
dc.subject.meshCOVID-19 Vaccines
dc.subject.meshSpike Glycoprotein, Coronavirus
dc.subject.meshSARS-CoV-2
dc.subject.meshProspective Studies
dc.subject.meshAntibodies, Viral
dc.subject.meshCOVID-19
dc.subject.meshAntibodies, Neutralizing
dc.subject.meshImmunoglobulin G
dc.subject.meshImmunosuppression Therapy
dc.subject.meshVaccination
dc.subject.meshImmunologic Deficiency Syndromes
dc.subject.meshHIV Infections
dc.subject.meshRNA, Messenger
dc.titleSevere immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number28
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC9144847.pdf
Size:
536.48 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen de Valme
Instituto de Investigación Biomédica de Sevilla (IBIS)
Instituto de Investigación Biosanitaria de Granada (ibsGRANADA)
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Universitario Reina Sofía
SAS - Hospital Universitario San Cecilio
Load more

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía